Indication
Viral Infection
8 clinical trials
16 products
1 drug
Product
VapendavirClinical trial
A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus ChallengeStatus: Recruiting, Estimated PCD: 2024-12-30
Product
PlaceboProduct
aH5N8cProduct
aH5N6cClinical trial
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations With H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects ≥18 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2024-04-25
Product
VB10.2129Product
VB10.2210Clinical trial
A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2022-12-16
Product
A/H2N3c + MF59Product
A/H2N3cClinical trial
A Phase 1, Randomized, Observer-Blind, Multi-Center, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-derived A/H2N3 Subunit Influenza Virus Vaccine in Healthy Subjects 18 Years and AboveStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Feasibility Study of Xofluza Treatment of Influenza in Pediatric Transplant Recipients, Waitlisted Subjects and Household Members After Early Infection Alerting Using Wearable DevicesStatus: Recruiting, Estimated PCD: 2024-05-31
Product
BaloxavirClinical trial
Multi-dose Oral Ondansetron For Pediatric Gastroenteritis: A Pragmatic Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-06-01
Product
OndansetronProduct
Oral PlaceboClinical trial
Randomized Controlled Clinical Study (RCT) Phase 3 of the Safety and Efficacy of Hypochlorous Acid in the Prophylaxis of Healthcare Personnel at High Risk of Infection by SARS-CoV2 (COVID19) Versus PlaceboStatus: Withdrawn, Estimated PCD: 2021-06-15
Product
Stabilized hypochlorous acidDrug
VarlilumabClinical trial
Predicting Severity and Disease Progression in Influenza-like IllnessStatus: Terminated, Estimated PCD: 2022-04-30
Product
Respiratory infections